PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.13%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
37.34%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
47.13%
Positive net income growth while CRVO is negative. John Neff might see a big relative performance advantage.
50.90%
Positive EPS growth while CRVO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
52.86%
Positive diluted EPS growth while CRVO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
7.67%
Share count expansion well above CRVO's 0.61%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
12.32%
Diluted share count expanding well above CRVO's 0.61%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
33.57%
OCF growth above 1.5x CRVO's 1.71%. David Dodd would confirm a clear edge in underlying cash generation.
33.08%
FCF growth above 1.5x CRVO's 2.30%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9761.92%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-7404.36%
Negative 5Y OCF/share CAGR while CRVO is at 96.25%. Joel Greenblatt would question the firm’s operational model or cost structure.
-3986.05%
Negative 3Y OCF/share CAGR while CRVO stands at 92.89%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-11268.60%
Negative 10Y net income/share CAGR while CRVO is at 2.07%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-11424.82%
Negative 5Y net income/share CAGR while CRVO is 97.80%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
97.34%
3Y net income/share CAGR similar to CRVO's 95.64%. Walter Schloss would attribute it to shared growth factors or demand patterns.
No Data
No Data available this quarter, please select a different quarter.
7616.79%
Positive 5Y equity/share CAGR while CRVO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
547.30%
3Y equity/share CAGR above 1.5x CRVO's 112.81%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.86%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.66%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-26.31%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-49.44%
We cut SG&A while CRVO invests at 21.57%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.